Biomarkers, PRO Tools Warrant Separate Qualification Guidelines, Groups Tell FDA
Executive Summary
FDA’s midstream decision to expand a biomarker qualification draft guidance to include patient-reported outcome tools has perplexed pharma stakeholders, which seem to think the agency would have been better off leaving well enough, and PROs, alone.
You may also be interested in...
Regulatory Science Next To Be Outsourced?
CDER report calls for broader partnerships with outside bodies in regulatory science.
FDA Drug Development Tool Guidance Leaves Door Open For Advisory Committee Reviews
FDA’s proposed process for qualifying drug development tools allows for the convening of advisory committee meetings or other public discussions about complicated submissions involving proposed biomarkers or patient-reported outcome instruments.
FDA's Forthcoming Drug Development Guidance: It's All About The Process
FDA's draft guidance on qualification won't discuss specific drug development tools but is expected out before the end of 2010 even after running into internal delays.